INCYTE CORPORATION (INCY) FY2026 Q2 P&L / Income Statement

Revenue by Product and Service by Arrangement

2026-04-01 to 2026-06-30

Swipe to see the full flow
INCYTE CORPORATION (INCY) FY2026 Q2 P&L / Income StatementIncome statement for 2026-04-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETJAKAFIProduct royalty revenuesJAKAVI - NovartisJAKAVI Royalty RevenuesUndisclosed (calculated)NIKTIMVOMINJUVI/MONJUVIZYNYZOLUMIANT - Eli LillyOLUMIANT Royalty RevenuesICLUSIGPEMAZYREMilestone and contract revenuesTABRECTA - NovartisTABRECTA Royalty RevenuesOtherTotal revenuesGross profit (calculated)Cost of sales (including definite-lived intangible amortization)Income from operationsOperating expenses (calculated)Research and developmentSelling, general and administrativeLoss on change in fair value of acquisition-related contingent considerationOther income (expense), net (calculated)Income before provision for income taxesNet incomeProvision for income taxesOther income (expense), net (calculated)Other income,net (calculated)$53.62 MIncome before provision for income taxesIncome beforeprovision forincome taxes$751.51 MGross profit (calculated)Gross profit(calculated)$1.57 BTotal revenuesTotal revenues$1.67 BIncome from operationsIncome from operations$697.90 MNet incomeNet income$585.61 MJAKAFIJAKAFI$816.66 MOperating expenses (calculated)Operating expenses(calculated)$871.18 MProvision for income taxesProvision forincome taxes$165.91 MProduct royalty revenuesProduct royalty revenues$174.69 MJAKAVI - NovartisJAKAVI - Novartis$124.20 MResearch and developmentResearch and development$516.95 MJAKAVI Royalty RevenuesJAKAVI$124.19 MCost of sales (including definite-lived intangible amortization)Cost of sales$104.96 MSelling, general and administrativeSelling, general and administrative$351.74 MUndisclosed (calculated)Undisclosed (calculated)$105.65 MLoss on change in fair value of acquisition-related contingent considerationLoss on change in fairvalue of acquisition-relatedcontingent consideration$2.50 MNIKTIMVONIKTIMVO$60.31 MMINJUVI/MONJUVIMINJUVI/MONJUVI$53.69 MZYNYZZYNYZ$49.95 MOLUMIANT - Eli LillyOLUMIANT - Eli Lilly$38.50 MOLUMIANT Royalty RevenuesOLUMIANT$38.48 MICLUSIGICLUSIG$34.39 MPEMAZYREPEMAZYRE$23.42 MMilestone and contract revenuesMilestone and contract revenues$11.20 MTABRECTA - NovartisTABRECTA - Novartis$6.70 MTABRECTA Royalty RevenuesTABRECTA$6.69 MOtherOther$5.33 M
Chart details

INCYTE CORPORATION (INCY) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
1,674,039,000 US dollars
Cost of sales (including definite-lived intangible amortization)
104,957,000 US dollars
Gross profit (calculated)
1,569,082,000 US dollars
Operating expenses (calculated)
871,184,000 US dollars
Income from operations
697,898,000 US dollars
Other income (expense), net (calculated)
53,616,000 US dollars
Income before provision for income taxes
751,514,000 US dollars
Provision for income taxes
165,909,000 US dollars
Net income
585,605,000 US dollars
ICLUSIG
34,394,000 US dollars
JAKAFI
816,659,000 US dollars
JAKAVI Royalty Revenues
124,190,000 US dollars
MINJUVI/MONJUVI
53,686,000 US dollars
Milestone and contract revenues
11,200,000 US dollars
NIKTIMVO
60,309,000 US dollars
OLUMIANT Royalty Revenues
38,479,000 US dollars
Other
5,330,000 US dollars
PEMAZYRE
23,418,000 US dollars
TABRECTA Royalty Revenues
6,691,000 US dollars
ZYNYZ
49,947,000 US dollars
Product royalty revenues
174,690,000 US dollars
JAKAVI - Novartis
124,200,000 US dollars
OLUMIANT - Eli Lilly
38,500,000 US dollars
TABRECTA - Novartis
6,700,000 US dollars
Undisclosed (calculated)
105,646,000 US dollars
Research and development
516,950,000 US dollars
Selling, general and administrative
351,735,000 US dollars
Asset impairment and related disposal costs
0 US dollars
Loss on change in fair value of acquisition-related contingent consideration
2,499,000 US dollars
Contract dispute settlement
0 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
INCYTE CORPORATION (INCY) FY2026 Q2 P&L / Income Statement Sankey chart, Product and service — Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

93.7%

Gross profit / revenue

Operating margin

41.7%

Operating profit / revenue

Cash conversion

86.7%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!